Compare · CBUS vs NXTS
CBUS vs NXTS
Side-by-side comparison of Cibus Inc. (CBUS) and Nexentis Technologies Inc. (NXTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBUS and NXTS operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CBUS is the larger of the two at $134.3M, about 40.4x NXTS ($3.3M).
- Over the past year, CBUS is up 8.9% and NXTS is down 96.7% - CBUS leads by 105.6 points.
- NXTS has hit the wire 6 times in the past 4 weeks while CBUS has been quiet.
- CBUS has more recent analyst coverage (4 ratings vs 0 for NXTS).
PerformanceCBUS+5.78%NXTS-96.68%
2025-07-22+0.00%2026-07-21
- Company
- Cibus Inc.
- Nexentis Technologies Inc.
- Price
- $1.83+3.39%
- $2.17-14.09%
- Market cap
- $134.3M
- $3.3M
- 1M return
- +35.56%
- -62.80%
- 1Y return
- +8.93%
- -96.68%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 0
- 6
- Recent ratings
- 4
- 0
Latest CBUS
- SEC Form S-8 filed by Cibus Inc.
- SEC Form S-8 filed by Cibus Inc.
- Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus
- CEO Wichner Craig was granted 894,309 shares (SEC Form 4)
- Cibus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation
- Cibus Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Finn Mark Terrence
- SEC Form 4 filed by Director Moretti August J
- SEC Form 4 filed by Director Riggs Rory B
Latest NXTS
- SEC Form EFFECT filed by Nexentis Technologies Inc.
- SEC Form EFFECT filed by Nexentis Technologies Inc.
- SEC Form S-1 filed by Nexentis Technologies Inc.
- SEC Form POS AM filed by Nexentis Technologies Inc.
- Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
- Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
- SEC Form 424B5 filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
- Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases